Prader-Willi syndrome: From genetics to behaviour, with special focus on appetite treatments

Neuroscience and Biobehavioral Reviews

Volumn 59, Issue , 2015, Pages 155-172

  Griggs, Joanne L ^a   Sinnayah, Puspha ^a   Mathai, Michael L ^a  

^a VICTORIA UNIVERSITY   (Australia)

Author keywords

Appetite behaviour; Hyperphagia; Obesity; Pharmaceutical or treatment and hypothalamus; Prader Willi syndrome

Indexed keywords

BELORANIB; CHLORDIAZEPOXIDE; EXENDIN 4; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; GHRELIN; HUMAN GROWTH HORMONE; INSULIN ASPART; INSULIN GLARGINE; MAZINDOL; METFORMIN; NALOXONE; NALTREXONE; OCTREOTIDE; OXYTOCIN; PANCREAS POLYPEPTIDE; PHENOTHIAZINE; PLACEBO; RIMONABANT; RISPERIDONE; TOPIRAMATE;

AUTISM; CHROMOSOME 15; COGNITIVE THERAPY; DIET RESTRICTION; DRUG DOSE INCREASE; ENERGY BALANCE; ENERGY EXPENDITURE; GROWTH HORMONE DEFICIENCY; HUMAN; HUNGER; HYPERPHAGIA; INTELLECTUAL IMPAIRMENT; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OBSESSIVE COMPULSIVE DISORDER; PRADER WILLI SYNDROME; PRIORITY JOURNAL; REVIEW; SATIETY; ANIMAL; APPETITE; BEHAVIOR; EATING; GENETICS; METABOLISM; PHYSIOLOGY; PRADER-WILLI SYNDROME;

ANIMALS; APPETITE; BEHAVIOR; EATING; HUMANS; HYPERPHAGIA; OBSESSIVE-COMPULSIVE DISORDER; PRADER-WILLI SYNDROME;

EID: 84956889677     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2015.10.003     Document Type: Review

References (126)

1. Abreu, A.P., Macedo, D.B., Brito, V.N., Kaiser, U.B., Latronico, A.C., 2015. A new pathway in the control of the initiation of puberty: the MKRN3 gene. J. Mol. Endocrinol. 54, R131-R139
2. Angulo, M., Butler, M., Cataletto, M., 2015. Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J. Endocrinol. Investig., 1-15
3. Araki, S., Ohji, T., Shiota, N., Dobashi, K., Shimono, M., Shirahata, A., 2010.Successful risperidone treatment for behavioral disturbances in Prader-Willi syndrome. Pediatr. Int. 52, e1e3
4. Asakawa, A., et al., 2001. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120, 337-345
5. Asakawa, A., Inui, A., Kaga, O., Yuzuriha, H., Nagata, T., Ueno, N., Makino, S., Fujimiya, M., Niijima, A., Aycan, Z., Baş, V.N., 2014. Prader-Willi syndrome and growth hormone deficiency. J. Clin. Res. Pediatr. Endocrinol. 6, 62-67
6. Badman, M.K., Flier, J.S., 2005. The gut and energy balance: visceral allies in the obesity wars. Science 307, 1909-1914
7. Baron-Cohen, S., 2001. Theory of mind and autism: a review. Int. Rev. Res. Ment. Retard.: Autism 23, 169-184
8. Bays, H.E., 2004. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes. Res. 12, 1197-1211
9. Benelam, B., 2009. Satiation, satiety and their effects on eating behaviour. Nutr. Bull. 34, 126173
10. Benjamin, E., Buot-Smith, T., 1993. Naltrexone and fluoxetine in Prader-Willi syndrome. J. Am. Acad. Child Adolesc. Psychiatry 32, 870-873
11. Berntson, G.G., Zipf, W.B., O'Dorisio, T.M., Hoffman, J.A., Chance, R.E., 1993. Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome. Peptides 14, 497-503
12. Bertella, L., Mori, I., Grugni, G., Pignatti, R., Ceriani, F., Molinari, E., Ceccarelli, A., Sartorio, A., Vettor, R., Semenza, C., 2007. Quality of life and psychological well-being in GH-treated, adult PWS patients: a longitudinal study. J. Intellect. Disabil. Res. 51, 302-311
13. Bittel, D.C., Kibiryeva, N., Butler, M.G., 2006. Expression of 4 genes between chromosome 15 breakpoints 1 and 2 and behavioral outcomes in Prader-Willi syndrome. Pediatrics 118, e1276-e1283
14. Boyle, C., Scriven, B., Durning, S., Downes, C., 2011. Facilitating the learning of all students: the 'professional positive' of inclusive practice in Australian primary schools. Support Learn. 26, 72-78
15. Brambilla, P., Bosio, L., Manzoni, P., Pietrobelli, A., Beccaria, L., Chiumello, G., 1997. Peculiar body composition in patients with Prader-Labhart-Willi syndrome. Am. J. Clin. Nutr. 65, 1369-1374
16. Bridges, N., 2014. What is the value of growth hormone therapy in Prader-Willi syndrome? Arch. Dis. Child. 99, 166-170
17. Briggs, D.I., Enriori, P.J., Lemus, M.B., Cowley, M.A., Andrews, Z.B., 2010.Diet-induced obesity causes ghrelin resistance in arcuate NPY/AgRP neurons. Endocrinology 151, 4745-4755
18. Buczko, W., De Gaetano, G., Garattini, S., 1975. Effect of fenfluramine on 5-hydroxytryptamine uptake and release by rat blood platelets. Br. J. Pharmacol. 53, 563-568
19. Burman, P., Ritzen, E.M., Lindgren, A.C., 2001. Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. Endocr. Rev. 22, 787-799
20. Butler, J., Whittington, J., Holland, A.J., McAllister, C.J., Goldstone, A.P., 2010.The transition between the phenotypes of Prader-Willi syndrome during infancy and early years. Dev. Med. Child Neurol., e88-e93
21. Butler, M.G., Carlson, M.G., Schmidt, D.E., Feurer, I.D., Thompson, T., 2000. Plasma cholecystokinin levels in Prader-Willi syndrome and obese subjects. Am. J. Med. Genet. 95, 67-70
22. Cacciari, E., Zucchini, S., Carla, G., Pirazzoli, P., Cicognani, A., Mandini, M., Busacca, M., Trevisan, C., 1990. Endocrine function and morphological findings in patients with disorders of the hypothalamo-pituitary area: a study with magnetic resonance. Arch. Dis. Child. 65, 1199-1202
23. Canton, H., Emeson, R.B., Barker, E.L., Backstrom, J.R., Lu, J.T., Chang, M.S., Sanders-Bush, E., 1996. Identification, molecular cloning, and distribution of a short variant of the 5-hydroxytryptamine 2C receptor produced by alternative splicing. Mol. Pharmacol. 50, 799-807
24. Carrel, A.L., Myers, S.E., Whitman, B.Y., Allen, D.B., 1999. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: a controlled study. J. Pediatr. 134, 215-221
25. Cassidy, S.B., Driscoll, D.J., 2009. Prader-Willi syndrome. Eur. J. Hum. Genet. 17, 3-13
26. Cassidy, S.B., Schwartz, S., Miller, J.L., Driscoll, D.J., 2011. Prader-Willi syndrome. Genet. Med. 14, 10-26
27. Chamberlain, S.J., Lalande, M., 2010.Neurodevelopmental disorders involving genomic imprinting at human chromosome 15q11-q13. Neurobiol. Dis. 39, 13-20
28. Chen, C., Visootsak, J., Dills, S., John Jr., M.G., 2007. Prader-Willi syndrome: an update and review for the primary pediatrician. Clin. Pediatr. 46, 580-591
29. Chevalère, J., Postal, V., Jauregui, J., Copet, P., Laurier, V., Thuilleaux, D., 2013. Assessment of executive functions in Prader-Willi syndrome and relationship with intellectual level. J. Appl. Res. Intellect. Disabil. 26, 309-318
30. Clarke, D.J., Boer, H., Whittington, J., Webb, T., 2002. Prader-Willi syndrome, compulsive and ritualistic behaviours: the first population-based survey. Br. J. Psychiatry 180, 358-362
31. Cnop, M., Havel, P., Utzschneider, K., Carr, D., Sinha, M., Boyko, E., Retzlaff, B., Knopp, R., Brunzell, J., 2003. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46, 459-469
32. Conant, K.D., Finucane, B., Cleary, N., Martin, A., Muss, C., Delany, M., et al., 2014. A survey of seizures and current treatments in 15q duplication syndrome. Epilepsia 55 (3), 396-402
33. Cowley, M.A., 2003. Hypothalamic melanocortin neurons integrate signals of energy state. Eur. J. Pharmacol. 480, 3-11
34. Cowley, M., et al., 2003. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 37, 649-661
35. Cummings, D.E., et al., 2002. Elevated plasma ghrelin levels in Prader-Willi syndrome. Nat. Med. 8, 643-644
36. Deal, C.L., Tony, M., Höybye, C., Allen, D.B., Tauber, M., Christiansen, J.S., Ambler, G.R., Battista, R., Beauloye, V., Berall, G., 2013. Growth Hormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 98, E1072-E1087
37. DelParigi, A., Tschöp, M., Heiman, M.L., Salbe, A.D., Vozarova, B., Sell, S.M., Bunt, J.C., Tataranni, P.A., 2002. High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 87, 5461-5464
38. Desch, L., Marle, N., Mosca-Boidron, A.-L., Faivre, L., Eliade, M., Payet, M., Ragon, C., Thevenon, J., Aral, B., Ragot, S., 2015. 6q16.3q23.3 duplication associated with Prader-Willi-like syndrome. Mol. Cytogenet. 8, 1-5
39. De Waele, K., Ishkanian, S.L., Bogarin, R., Miranda, C.A., Ghatei, M.A., Bloom, S.R., Pacaud, D., Chanoine, J.-P., 2008. Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome. Eur. J. Endocrinol./Eur. Fed. Endocr. Soc. 159, 381-388
40. Dimitropoulos, A., Feurer, I.D., Roof, E., Stone, W., Butler, M.G., Sutcliffe, J., Thompson, T., 2000. Appetitive behavior, compulsivity, and neurochemistry in Prader-Willi syndrome. Mental Retard. Dev. Disabil. Res. Rev. 6, 125-130
41. Dimitropoulos, A., Ho, A.Y., Klaiman, C., Koenig, K., Schultz, R.T., 2009. A comparison of behavioral and emotional characteristics in children with autism, Prader-Willi syndrome, and Williams syndrome. J. Mental Health Res. Intellect. Disabil. 2, 220243
42. Ding, F., Li, H.H., Zhang, S., Solomon, N.M., Camper, S.A., Cohen, P., Francke, U., 2008. SnoRNA Snord116 (Pwcr1/MBII-85) deletion causes growth deficiency and hyperphagia in mice. PLoS ONE 3, e1709
43. Doe, C.M.D.R., Garfield, A.S., Dalley, J.W., Theobald, D., Humby, T., Wilkonson, L., Isles, A., 2009. Loss of the imprinted snoRNA mbii-52 leads to increased 5htr2c pre-RNA editing and altered 5HT2cR-mediated behaviour. Hum. Mol. Genet. 18, 2140-2148
44. Druce, M.R., Small, C.J., Bloom, S.R., 2004. Minireview: gut peptides regulating satiety. Endocrinology 145, 2660-2665
45. Duffau, H., 2006. Brain plasticity: from pathophysiological mechanisms to therapeutic applications. J. Clin. Neurosci. 13, 885-897
46. Duker, A.L., Ballif, B.C., Bawle, E.V., Person, R.E., Mahadevan, S., Alliman, S., Thompson, R., Traylor, R., Bejjani, B.A., Shaffer, L.G., Rosenfeld, J.A., Lamb, A.N., Sahoo, T., 2010.Paternally inherited microdeletion at 15q11.2 confirms a significant role for the SNORD116C/D box snoRNA cluster in Prader-Willi syndrome. Eur. J. Hum. Genet. 18, 1196-1201
47. Durst, R., Rubin-Jabotinsky, K., Raskin, S., Katz, G., Zislin, J., 2001. Risperidone in treating behavioural disturbances of Prader-Willi syndrome. Acta Psychiatr. Scand. 102, 461465
48. Dykens, E.M., 2007. Assessment of hyperphagia in Prader-Willi syndrome. Obesity 15, 1816-1826
49. Dykens, E., Shah, B., 2003. Psychiatric disorders in Prader-Willi syndrome: epidemiology and management. CNS Drugs 17, 167-178
50. Dykens, E.M., 2013. Aging in rare intellectual disability syndromes. Dev. Disabil. Res. Rev. 18, 75-83
51. Dykens, E.M., Leckman, J., Cassidy, S.B., 1996. Obsessions and compulsions in Prader-Willi syndrome. J. Child Psychol. Psychiatry 37, 995-1002
52. Dykens, E.M., Roof, E., Bittel, D., Butler, M.G., 2011. TPH2 G/T polymorphism is associated with hyperphagia, IQ, and internalizing problems in Prader-Willi syndrome. J. Child Psychol. Psychiatry 52, 580-587
53. Dykens, E.M., Sutcliffe, J.S., Levitt, P., 2004. Autism and 15q11-q13 disorders: behavioral, genetic, and pathophysiological issues. Mental Retard. Dev. Disabil. Res. Rev. 10, 284-291
54. Einfeld, S.L., Smith, E., McGregor, I.S., Steinbeck, K., Taffe, J., Rice, L.J., Horstead, S.K., Rogers, N., Hodge, M.A., Guastella, A.J., 2014. A double-blind randomized controlled trial of oxytocin nasal spray in Prader-Willi syndrome. Am. J. Med. Genet. A 164, 2232-2239
55. Elliott, J.P., Cherpes, G., Kamal, K., Chopra, I., Harrison, C., Riedy, M., Herk, B., McCrossin, M., Kalarchian, M., 2015. Relationship between antipsychotics and weight in patients with Prader-Willi syndrome. Pharmacotherapy 35, 260-268
56. Farooqi, I.S., 2014. Defining the neural basis of appetite and obesity: from genes to behaviour. Clin. Med. 14, 286-289
57. Farooqi, I.S., O'Rahilly, S., 2009. Leptin: a pivotal regulator of human energy homeostasis. Am. J. Clin. Nutr. 89, 980S-984S
58. Fieldstone, A., Zipf, W.B., Sarter, M.F., Berntson, G.G., 1998. Food intake in Prader-Willi syndrome and controls with obesity after administration of a benzodiazepine receptor agonist. Obes. Res. 6, 29-33
59. Festen, D.A.M., de Lind van Wijngaarden, R., van Eekelen, M., Otten, B.J., Wit, J.M., Duivenvoorden, H.J., Fieldstone, A., Zipf, W.B., Sarter, M.F., Berntson, G.G., 1998. Food intake in Prader-Willi syndrome and controls with obesity after administration of a benzodiazepine receptor agonist. Obes. Res. 6, 29-33
60. Fulton, S., 2010.Appetite and reward. Front. Neuroendocrinol. 31, 85-103
61. Goldstone, A., Holland, A., Butler, J., Whittington, J., 2012. Appetite hormones and the transition to hyperphagia in children with Prader-Willi syndrome. Int. J. Obes. 36, 1564-1570
62. Griffin, K., Franklin, D., 1997. Can diet pills damage my heart? Health (Time Inc. Health) 11, 20
63. Goldstone, A.P., Holland, A.J., Hauffa, B.P., Hokken-Koelega, A.C., Tauber, M., 2008. Recommendations for the diagnosis and management of Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 93, 4183-4197
64. Goldstone, A.P., Patterson, M., Kalingag, N., Ghatei, M.A., Brynes, A.E., Bloom, S.R., Grossman, A.B., Korbonits, M., 2005. Fasting and postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma. J. Clin. Endocrinol. Metab. 90, 2681-2690
65. Goldstone, A.P., Thomas, E.L., Brynes, A.E., Bell, J.D., Frost, G., Saeed, N., Hajnal, J.V., Howard, J.K., Holland, A., Bloom, S.R., 2001. Visceral adipose tissue and metabolic complications of obesity are reduced in Prader-Willi syndrome female adults: evidence for novel influences on body fat distribution. J. Clin. Endocrinol. Metab. 86, 4330-4338
66. Goldstone, A.P., Unmehopa, U.A., Bloom, S.R., Swaab, D.F., 2002. Hypothalamic NPY and agouti-related protein are increased in human illness but not in Prader-Willi syndrome and other obese subjects. J. Clin. Endocrinol. Metab. 87, 927-937
67. Griggs, J.L., Xiao, S., Mathai, M.L., 2015. Caralluma fimbriata supplementation improves the appetite behaviour of children and adolescents with Prader-Willi syndrome. N. Am. J. Med. Sci. 7
68. Grugni, G., Beccaria, L., Corrias, A., Crinò, A., Cappa, M., De Medici, C., Di Candia, S., Gargantini, L., Ragusa, L., Salvatoni, A., Sartorio, A., Spera, S., Andrulli, S., Chiumello, G., Mussa, A., 2013. Central adrenal insufficiency in young adults with Prader-Willi syndrome. Clin. Endocrinol. 79, 371-378
69. Haqq, A.M., Grambow, S.C., Muehlbauer, M., Newgard, C.B., Svetkey, L.P., Carrel, A.L., Yanovski, J.A., Purnell, J.Q., Freemark, M., 2008. Ghrelin concentrations in Prader-Willi syndrome (PWS) infants and children: changes during development. Clin. Endocrinol. 69, 911-920
70. Han, C.K., Ahn, S.K., Choi, N.S., Hong, R.K., Moon, S.K., Chun, H.S., Lee, S.J., Kim, J.W., Hong, C.I., Kim, D., 2000. Design and synthesis of highly potent fumagillin analogues from homology modeling for a human MetAP-2. Bioorg. Med. Chem. Lett. 10, 39-43
71. Han, J.C., Muehlbauer, M.J., Cui, H.N., Newgard, C.B., Haqq, A.M., 2010.Lower brain-derived neurotrophic factor in patients with Prader-Willi syndrome compared to obese and lean control subjects. J. Clin. Endocrinol. Metab. 95, 3532-3536
72. Haqq, A.M., Stadler, D.D., Rosenfeld, R.G., Pratt, K.L., Weigle, D.S., Frayo, R.S., LaFranchi, S.H., Cummings, D.E., Purnell, J.Q., 2003. Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 88, 3573-3576
73. Hauffa, B.P., Haase, K., Range, I.M., Unger, N., Mann, K., Peterson, S., 2007. The effect of growth hormone on the response of total and acylated ghrelin to a standardized oral glucose load and insulin resistance in children with Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 92, 834-840
74. Haqq, A.M., Muehlbauer, M., Svetkey, L.P., Newgard, C.B., Purnell, J.Q., Grambow, S.C., Freemark, M.S., 2007. Altered distribution of adiponectin isoforms in children with Prader-Willi syndrome (PWS): association with insulin sensitivity and circulating satiety peptide hormones. Clin. Endocrinol. 67, 944-951
75. Haqq, A.M., Muehlbauer, M.J., Newgard, C.B., Grambow, S., Freemark, M., 2011. The metabolic phenotype of Prader-Willi syndrome (PWS) in childhood: heightened insulin sensitivity relative to body mass index. J. Clin. Endocrinol. Metab. 96, E225-E232
76. Herzog, H., 2012. Snord116 critical for regulation of energy homeostasis in PWS. In: 2nd Asia Pacific Prader-Willi Syndrome Conference March 2012, 10th of March
77. Heymsfield, S.B., et al., 2014. Hyperphagia: current concepts and future directions proceedings of the 2nd international conference on hyperphagia. Obesity 22, S1-S17
78. Hilaire, G., Voituron, N., Menuet, C., Ichiyama, R.M., Subramanian, H.H., Dutschmann, M., 2010.The role of serotonin in respiratory function and dysfunction. Respir. Physiol. Neurobiol. 174, 76-88
79. Hinton, E.C., Holland, A.J., Gellatly, M.S.N., Soni, S., Owen, A.M., 2006a. An investigation into food preferences and the neural basis of food-related incentive motivation in Prader-Willi syndrome. J. Intellect. Disabil. Res. 50, 633-642
80. Hinton, E.C., Holland, A.J., Gellatly, M.S.N., Soni, S., Patterson, M., Ghatei, M.A., Owen, A.M., 2006b. Neural representations of hunger and satiety in Prader-Willi syndrome. Int. J. Obes. 30, 313-321
81. Hinton, E.C., Holland, A.J., Owen, A.M., 2007. Functional neuroimaging in Prader-Willi syndrome, vol. 31. Nature Publishing Group, pp. 390-391
82. Hochberg, I., Hochberg, Z., 2010.Expanding the definition of hypothalamic obesity. Obes. Rev. 11, 709721
83. Hogart, A., Wu, D., LaSalle, J.M., Schanen, N.C., 2010.The comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13. Neurobiol. Dis. 38, 181-191
84. Holland, A., 2008. The paradox of Prader-Willi syndrome: a genetic model of starvation. J. Intellect. Disabil. Res. 52, 811
85. Holland, A., Whittington, J., Hinton, E., 2003. The paradox of Prader-Willi syndrome: a genetic model of starvation. Lancet 362, 989-991
86. Holm, V.A., Cassidy, S.B., Butler, M.G., Hanchett, J.M., Greenswag, L.R., Whitman, B.Y., Greenberg, F., 1993. Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 91, 398-402
87. Holson, L., Zarcone, J., Brooks, W.M., Butler, M., Thompson, T., Ahluwalia, J.S., Nollen, N.L., Savage, C.R., 2006. Neural mechanisms underlying hyperphagia in Prader-Willi syndrome. Obesity (Silver Spring) 14, 1028-1037
88. Höybye, C., Hilding, A., Jacobsson, H., Thorén, M., 2002. Metabolic profile and body composition in adults with Prader-Willi syndrome and severe obesity. J. Clin. Endocrinol. Metab. 87, 3590-3597
89. Inoue, S., 1995. Clinical studies with mazindol. Obes. Res. 3 (Suppl. 4), 549S-552S
90. Itoh, M., Koeda, T., Ohno, K., Takeshita, K., 1995. Effects of mazindol in two patients with Prader-Willi syndrome. Pediatr. Neurol. 13, 349-351
91. Jackowski, A.P., Laureano, M.R., Del'Aquilla, M.A., de Moura, L.M., Assunção, I., Silva, I., Schwartzman, J.S., 2011. Update on clinical features and brain abnormalities in neurogenetics syndromes. J. Appl. Res. Intellect. Disabil. 24, 217-236
92. Kantor, B., Shemer, R., Razin, A., 2006. The Prader-Willi/Angelman imprinted domain and its control center. Cytogenet. Genome Res. 113, 300-305
93. Kennedy, L., Bittel, D., Kibiryeva, N., Kalra, S., Torto, R., Butler, M., 2005. Circulating adiponectin levels, body composition and obesity-related variables in Prader-Willi syndrome: comparison with obese subjects. Int. J. Obes. 30, 382-387
94. Shapira, N.A., Lessig, M.C., Lewis, M.H., Goodman, W.K., Driscoll, D.J., 2004. Effects of topiramate in adults with Prader-Willi syndrome. Am. J. Mental Retard. 109, 301309
95. Sinnema, M., Schrander-Stumpel, C.T.R.M., Maaskant, M.A., Boer, H., Curfs, L.M.G., 2012b. Aging in Prader-Willi syndrome: twelve persons over the age of 50 years. Am. J. Med. Genet. A 158, 1326-1336
96. Smathers, S.A., Wilson, J.G., Nigro, M.A., 2003. Topiramate effectiveness in Prader-Willi syndrome. Pediatr. Neurol. 28, 130
97. Smith, A., Loughnan, G., Steinbeck, K., 2003. Death in adults with Prader-Willi syndrome may be correlated with maternal uniparental disomy. J. Med. Genet. 40, 1-4
98. Soni, S., Whittington, J., Holland, A.J., Webb, T., Maina, E., Boer, H., Clarke, D., 2007. The course and outcome of psychiatric illness in people with Prader-Willi syndrome: implications for management and treatment. J. Intellect. Disabil. Res. 51, 32-42
99. Steculorum, S.M., Collden, G., Coupe, B., Croizier, S., Lockie, S., Andrews, Z.B., Jarosch, F., Klussmann, S., Bouret, S.G., 2015. Neonatal ghrelin programs development of hypothalamic feeding circuits. J. Clin. Investig. 125, 846-858
100. Steinhausen, H.C., Eiholzer, U., Hauffa, B.P., Malin, Z., 2004. Behavioural and emotional disturbances in people with Prader-Willi syndrome. J. Intellect. Disabil. Res. 48, 4752
101. Swaab, D., 1997. Prader-Willi syndrome and the hypothalamus. Acta Paediatr. 86, 50-54
102. Sze, L., Purtell, L., Jenkins, A., Loughnan, G., Smith, E., Herzog, H., Sainsbury, A., Steinbeck, K., Campbell, L.V., Viardot, A., 2011. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 96, E1314-E1319
103. Talebizadeh, Z., Butler, M., 2005. Insulin resistance and obesity-related factors in Prader-Willi syndrome: comparison with obese subjects. Clin. Genet. 67, 230-239
104. Tan, T.M., Vanderpump, M., Khoo, B., Patterson, M., Ghatei, M.A., Goldstone, A.P., 2004. Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 89, 4162-4165
105. Tassone, F., Broglio, F., Gianotti, L., Arvat, E., Ghigo, E., Maccario, M., 2007. Ghrelin and other gastrointestinal peptides involved in the control of food intake. Mini Rev. Med. Chem. 7, 47-53
106. Tauber, M., Diene, G., Mimoun, E., Cabal-Berthoumieu, S., Mantoulan, C., Molinas, C., Muscatelli, F., Salles, J.P., 2014. Prader-Willi syndrome as a model of human hyperphagia. Front. Horm. Res. 42, 93-106
107. Thomson, A.K., 2010.The transition between the phenotypes of Prader-Willi syndrome during infancy and early childhood. Dev. Med. Child Neurol. 52, 506-507
108. Torres-Fuentes, C., Schellekens, H., Dinan, T.G., Cryan, J.F., 2015. A natural solution for obesity: bioactives for the prevention and treatment of weight gain. A review. Nutr. Neurosci. 18, 49-65
109. Tunnicliffe, P., Woodcock, K., Bull, L., Oliver, C., Penhallow, J., 2014. Temper outbursts in Prader-Willi syndrome: causes, behavioural and emotional sequence and responses by carers. J. Intellect. Disabil. Res. 58, 134-150
110. Tuysuz, B., et al., 2014. Prevalence of Prader-Willi syndrome among infants with hypotonia. J. Pediatr. 164, 1064-1067
111. Van Wijngaarden, R., Otten, B., Festen, D., Joosten, K., De Jong, F., Sweep, F., Hokken-Koelega, A., 2008. High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 93, 1649-1654
112. Williams, C.A., 1995. Angelman syndrome: consensus for diagnostic criteria. Am. J. Med. Genet. 56 (2), 237-238
113. Whittington, J., Holland, A., 2010.Neurobehavioral phenotype in Prader-Willi syndrome. Am. J. Med. Genet. C Sem. Med. Genet. 154C, 438-447
114. Whittington, J., Holland, T., 2011. Recognition of emotion in facial expression by people with Prader-Willi syndrome. J. Intellect. Disabil. Res. 55, 75-84
115. Whittington, J.E., Holland, A.J., Webb, T., Butler, J., Clarke, D., Boer, H., 2002. Relationship between clinical and genetic diagnosis of Prader-Willi syndrome. J. Med. Genet., 926-932
116. Wylie, C.J., Hendricks, T.J., Zhang, B., Wang, L., Lu, P., Leahy, P., Fox, S., Maeno, H., Deneris, E.S., 2010.Distinct transcriptomes define rostral and caudal serotonin neurons. J. Neurosci. 30, 670-684
117. Yamada, K., Matsuzawa, H., Uchiyama, M., Kwee, I.L., Nakada, T., 2006. Brain developmental abnormalities in Prader-Willi syndrome detected by diffusion tensor imaging. Pediatrics 118, e442-e448
118. Yearwood, E.L., McCulloch, M.R., Tucker, M.L., Riley, J.B., 2011. Care of the patient with Prader-Willi syndrome. MEDSURG Nurs. 20, 113-122
119. Yosten, G.L.C., Samson, W.K., 2010.The melanocortins, not oxytocin, mediate the anorexigenic and antidipsogenic effects of neuronostatin. Peptides 31, 1711-1714
120. Zanella, S., Watrin, F., Mebarek, S., Marly, F., Roussel, M., Gire, C., Diene, G., Tauber, M., Muscatelli, F., Hilaire, G., 2008. Necdin plays a role in the serotonergic modulation of the mouse respiratory network: implication for Prader-Willi syndrome. J. Neurosci. 28, 1745-1755
121. Zhang, Q., Bouma, G.J., McClellan, K., Tobet, S., 2012. Hypothalamic expression of snoRNA Snord116 is consistent with a link to the hyperphagia and obesity symptoms of Prader-Willi syndrome. Int. J. Dev. Neurosci. 30, 479-485
122. Zhang, Y., Zhao, H., Qiu, S., Tian, J., Wen, X., Miller, J.L., Deneen, K.M., Zhou, Z., Gold, M.S., Liu, Y., 2013a. Altered functional brain networks in Prader-Willi syndrome. NMR Biomed. 26, 622-629
123. Zhang, Z., Falaleeva, M., Agranat-Tamir, L., Pages, A., Eyras, E., Sperling, J., Sperling, R., Stamm, S., 2013b. The 5' untranslated region of the serotonin receptor 2C pre-mRNA generates miRNAs and is expressed in non-neuronal cells. Exp. Brain Res. 230, 387-394
124. Zipf, W.B., Bernston, G.G., 1987. Characteristics of abnormal food-intake patterns in children with Prader-Willi syndrome and study of effects of naloxone. Am. J. Clin. Nutr. 46, 277-281
125. Zipf, W.B., O'Dorisio, T.M., Bernston, G.G., 1990. Short-term infusion of pancreatic polypeptide: effect on children with Prader-Willi syndrome. Am. J. Clin. Nutr. 51, 162-166
126. Zlotkin, S.H., Fettes, I.M., Stallings, V.A., 1986. The effects of naltrexone, an oral beta-endorphin antagonist, in children with the Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 63, 1229-1232